← Human Trials & Peer-Reviewed Studies
Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide
Plain-language guide to PMID 27977473 (2017): double-blind randomized controlled trial study of PT-141 (Bremelanotide) and Alpha-MSH in 397 women, low blood pressure and orthostatic hypotension.
Key Facts
- PMID
- 27977473
- Journal
- Journal of hypertension
- Year
- 2017
- Study type
- Randomized Controlled Trial
- Authors
- White WB et al. (4 authors)
- DOI
- 10.1097/HJH.0000000000001221
What This Study Did, in Plain Language
What Was Tested
Researchers studied PT-141 (Bremelanotide) and Alpha-MSH in the context of low blood pressure and orthostatic hypotension in this randomized controlled trial publication.
Bremelanotide is an on-demand, subcutaneous melanocortin-receptor agonist that binds to the melanocortin receptor 4 and is being developed for the treatment of female sexual dysfunction.
Who Took Part
The abstract describes 397 women taking part.
The age groups tagged for this paper are young adults, adults and middle-aged adults, women only.
How the Study Was Run
The design is described as randomized, double-blind, placebo-controlled and parallel-group.
Because people in this PT-141 (Bremelanotide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
As a double-blind PT-141 (Bremelanotide) study, the assignments were hidden from both participants and investigators until the end.
A placebo (an inactive look-alike) gave the PT-141 (Bremelanotide) group a baseline to be compared against.
Groups ran in parallel: each of the women stayed in one arm throughout.
What Was Measured
The subject headings attached to it are Blood Pressure, Blood Pressure Monitoring, Ambulatory, Heart Rate, Peptides, Cyclic, Receptor, Melanocortin, Type 4, Sexual Dysfunctions, Psychological and alpha-MSH.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of PT-141 (Bremelanotide) and Alpha-MSH in 397 women in people with low blood pressure and orthostatic hypotension.
With several hundred people or more, it is a fairly large study for this kind of research.
The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2017 (Journal of hypertension), a journal based in Netherlands.
More context: the PT-141 (Bremelanotide) compound page and the Alpha-MSH compound page, Low blood pressure and orthostatic hypotension research.
Our Notes on the Compounds
PT-141 (Bremelanotide): A melanocortin (MC4R) agonist that acts on arousal centers in the brain.
Alpha-MSH: A 13-amino-acid hormone that drives skin pigmentation and calms inflammation; afamelanotide (Melanotan I) is an analog.
Related Pages
- Low blood pressure and orthostatic hypotension research
- PT-141 (Bremelanotide) in the library
- Alpha-MSH in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.